{"nctId":"NCT01103323","briefTitle":"Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","startDateStruct":{"date":"2010-04"},"conditions":["Metastatic Colorectal Cancer"],"count":760,"armGroups":[{"label":"Regorafenib (Stivarga, BAY73-4506)+BSC","type":"EXPERIMENTAL","interventionNames":["Drug: Regorafenib (Stivarga, BAY73-4506)","Other: Best Supportive Care (BSC)"]},{"label":"Placebo+BSC","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Other: Best Supportive Care (BSC)"]}],"interventions":[{"name":"Regorafenib (Stivarga, BAY73-4506)","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Best Supportive Care (BSC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological or cytological documentation of adenocarcinoma of the colon or rectum\n* Progression during or within 3 months following the last administration of approved standard therapies. Patients treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy\n* Patients with measurable or non measurable disease\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of \\</= 1\n* Life expectancy of at least 3 months\n* Adequate bone marrow, liver and renal function\n\nExclusion Criteria:\n\n* Unstable/uncontrolled cardiac disease\n* History of arterial or venous thrombotic or embolic events\n* Symptomatic metastatic brain or meningeal tumors\n* Patients with evidence or history of bleeding diathesis\n* Interstitial lung disease - Persistent proteinuria \\>/= grade 3\n* Unresolved toxicity \\> grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity \\</= Grade 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the time (days) from randomization to death due to any cause. Patients alive at the time of analysis were censored at the last date known to be alive. If a patient was lost to follow-up and there was no contact after randomization, this patient was censored at Day 1.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (Based on Investigator's Assessment)","description":"Progression-free survival was defined as the time (days) from date of randomization to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurred before progression was documented.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Tumor Response","description":"The objective tumor response was defined as the percentage of patients with complete response (CR, tumor disappears) or partial response (PR, sum of lesion sizes decreased at least 30% from baseline) as best overall response. A best overall response was defined for all patients, using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. Patients whose best overall response was not CR or PR, and any patients with no post-baseline assessments were considered nonresponders for the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control","description":"Disease control was defined as the percentage of patients whose best response was not PD \\[sum of lesion sizes increased at least 20% from smallest sum on study or new lesions\\] (ie, CR \\[tumor disappears\\], PR \\[sum of lesion sizes decreased at least 30% from baseline\\] or SD (stable disease)). SD included if at least 6 weeks after randomization.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Tumor Response","description":"A tumor response (best overall response) was defined for all patients, using the RECIST criteria, version 1.1. Categories: complete response (CR, tumor disappears), partial response (PR, sum of lesion sizes decreased at least 30% from baseline), stable disease (SD, steady state of disease), progressive disease (PD, sum of lesion sizes increased at least 20% from smallest sum on study or new lesions). Clinical PD considered when radiographic imaging not possible.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":null},{"groupId":"OG001","value":"14.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.5","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":232,"n":500},"commonTop":["Fatigue","Anorexia","Diarrhea","Hand-foot skin reaction","Weight loss"]}}}